Key facts
- This page summarizes Ajay Madan's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2022, 20:00.
Ajay Madan - 28 Feb 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- CRNX
- Reported as of
- 28 Feb 2022
- Net transaction value
- +$178,920
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2022, 20:00:35 UTC
- Prior SEC filing
- 09 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc Wilson, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ajay Madan filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 02 Mar 2022.
Change
- Previous filing in this sequence was filed on 09 Feb 2022.
- Current net transaction value: +$178,920.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +13,950
- Change %
- +8.1%
- Price
- $0.000000
- Shares after
- 185,995
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
CRNX
transaction
Common Stock
Sale
- Transaction value
- $178,920
- Shares
- +9,000
- Change %
- +5.4%
- Price
- $19.88
- Shares after
- 176,995
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Common Stock (right to buy)
Award
- Transaction value
- $0
- Shares
- +65,400
- Change %
- Price
- $0.000000
- Shares after
- 65,400
- Date
- 28 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,400
- Exercise price
- $20.02
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.
Footnote F2
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
Footnote F3
The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.